Eledon Pharmaceuticals to Unveil Long-Term Tegoprubart Data at American Transplant Congress
Event summary
- Eledon Pharmaceuticals will present new long-term data from the Phase 2 BESTOW trial of tegoprubart at the American Transplant Congress on June 22, 2026.
- The presentation will include updated safety and efficacy data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study.
- Andrew Adams, M.D., Ph.D., will deliver the oral presentation on June 22, 2026, from 12:03 p.m. – 12:15 p.m. ET.
- A conference call will be held on June 22, 2026, at 8:00 a.m. Eastern Time to discuss the presented data.
The big picture
Eledon Pharmaceuticals is positioning tegoprubart as a key player in the kidney transplant rejection space, leveraging its high-affinity anti-CD40L antibody to modulate immune responses. The presentation of long-term data at the American Transplant Congress is a critical milestone in validating the therapeutic potential of tegoprubart, which could reshape the treatment paradigm for kidney transplant patients. The broader industry is watching closely, as successful outcomes could accelerate the adoption of immune-modulating therapies in transplantation.
What we're watching
- Clinical Efficacy
- How the long-term safety and efficacy data from the BESTOW trial will impact the regulatory pathway for tegoprubart.
- Market Positioning
- Whether Eledon can leverage these data to differentiate tegoprubart in the competitive landscape of kidney transplant rejection therapies.
- Investor Sentiment
- The pace at which investor confidence in Eledon's pipeline will be affected by the presentation of these clinical results.
Related topics